摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[1-[[(1S)-1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid

中文名称
——
中文别名
——
英文名称
2-[1-[[(1S)-1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
英文别名
——
2-[1-[[(1S)-1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid化学式
CAS
——
化学式
C35H36ClNO3S
mdl
——
分子量
586.2
InChiKey
UCHDWCPVSPXUMX-YTTGMZPUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.7
  • 重原子数:
    41
  • 可旋转键数:
    12
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    95.7
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS
    申请人:Dugar Sundeep
    公开号:US20140121367A1
    公开(公告)日:2014-05-01
    The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.
    本发明涉及合成和应用新型手性/无手性取代甲基甲酰试剂来修饰药物和/或生物活性物质,以改变未经修饰的原始试剂的物理化学、生物学和/或药代动力学性质,从而得到改性后的化合物。
  • G PROTEIN-COUPLED PURINERGIC RECEPTOR Gpr17 MEDIATES OREXIGENIC EFFECTS OF FOXO1 IN AGRP NEURONS
    申请人:THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    公开号:US20150087690A1
    公开(公告)日:2015-03-26
    G protein-coupled receptor (GPCR) Gpr17 expressed in hypothalamic Agouti-related peptide-expressing (AgRP) neurons increases appetite and glucose tolerance and insulin sensitivity. By contrast, increasing Gpr17 reduced glucose tolerance and increased appetite. Gpr17-agonists had no effect on FoxO1-deficient mice, indicating, together with other data, that Gpr17 is a Fox-O1 target. Certain embodiments are directed to methods for reducing appetite, increasing glucose tolerance and insulin sensitivity and treating diabetes by administering Gpr17 antagonists or inhibitory oligonucleotides. Appetite can be increased by administering Gpr17 agonists.
  • US9309514B2
    申请人:——
    公开号:US9309514B2
    公开(公告)日:2016-04-12
  • US9359376B2
    申请人:——
    公开号:US9359376B2
    公开(公告)日:2016-06-07
查看更多